Trial reportDrug and alcohol dependence2012
The isoflavone puerarin reduces alcohol intake in heavy drinkers: a pilot study.
Trial report in Drug and alcohol dependence, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 65 citations in OpenAlex.
- A single dose of kudzu extract reduces alcohol consumption in a binge drinking paradigm.Drug and alcohol dependence · 2015Trial
- Development of reference materials for dietary supplements-analytical challenges, use, limitations, and future needs.Analytical and bioanalytical chemistry · 2025Review
- Investigating the Potential Therapeutic Mechanisms of Puerarin in Neurological Diseases.Molecular neurobiology · 2024Review
- Puerarin: a hepatoprotective drug from bench to bedside.Chinese medicine · 2024Review
- A mixture ofHeliyon · 2024Article
- Alcohol metabolism in alcohol use disorder: a potential therapeutic target.Alcohol and alcoholism (Oxford, Oxfordshire) · 2024Review
- A Complex Interplay between Nutrition and Alcohol use Disorder: Implications for Breaking the Vicious Cycle.Current pharmaceutical design · 2024Review
- Insight into Lotusine and Puerarin in Repairing Alcohol-Induced Metabolic Disorder Based on UPLC-MS/MS.International journal of molecular sciences · 2022Article
- Can gene therapy be used to prevent cancer? Gene therapy for aldehyde dehydrogenase 2 deficiency.Cancer gene therapy · 2022Review
- Development of Kudzu (Pueraria Montana var. lobata) Reference Materials for the Determination of Isoflavones and Toxic Elements.Journal of AOAC International · 2022Article
- Protective effect of isoflavones and triterpenoid saponins from pueraria lobata on liver diseases: A review.Food science & nutrition · 2022Review
- Differential Influence ofPharmaceuticals (Basel, Switzerland) · 2021Article
- Effects of Puerarin on the Prevention and Treatment of Cardiovascular Diseases.Frontiers in pharmacology · 2021Review
- Molecular Mechanisms of Anticancer Activities of Puerarin.Cancer management and research · 2020Review
- Applications ofChinese herbal medicines · 2019Article
- Soy Isoflavone Extract Does Not Increase the Intoxicating Effects of Acute Alcohol Ingestion in Human Volunteers.Frontiers in pharmacology · 2019Article
- Puerarin Mitigates Diabetic Hepatic Steatosis and Fibrosis by Inhibiting TGF-Oxidative medicine and cellular longevity · 2018Article
- Altering ethanol pharmacokinetics to treat alcohol use disorder: Can you teach an old dog new tricks?Journal of psychopharmacology (Oxford, England) · 2017Review
- Preparation, characterization and in vitro/vivo evaluation of tectorigenin solid dispersion with improved dissolution and bioavailability.European journal of drug metabolism and pharmacokinetics · 2016Article
- hVMAT2: A Target of Individualized Medication for Parkinson's Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundIsoflavone compounds naturally occurring in the root of the kudzu plant have been used historically to treat alcohol-related problems. A pilot study was conducted to assess the effects of one primary isoflavone--puerarin--for its ability to modify alcohol intake in humans.
methodsTen (10) healthy adult volunteers were administered puerarin (1200 mg daily) in a double-blind, placebo-controlled, crossover design experiment for one week prior to an afternoon drinking session lasting 1.5h. Participants had access to up to six bottles of their preferred brand of beer in addition to juice and water. A time course of drinking, sip volumes, and total amount consumed were recorded.
resultsParticipants consumed on average 3.5 (±0.55) beers when treated with placebo and 2.4 (±0.41) beers when treated with puerarin. In contrast to drinking following placebo treatment when 3 participants drank 5 beers and 1 participant drank all 6 beers, none drank 5 or 6 beers when treated with puerarin. Drinking topography also changed. When treated with puerarin, participants decreased sip size, took more sips to finish a beer, and took longer to consume each beer. Additionally, after finishing a beer, latency to opening the next beer was increased.
conclusionsThis study is the first demonstration that a single isoflavone found in the kudzu root can alter alcohol drinking in humans. These results suggest that alcohol consumption patterns are influenced by puerarin administration and this botanical medication may be a useful adjunct in the treatment of excessive alcohol intake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.